The optimal range of serum intact parathyroid hormone for a lower risk of mortality in the incident hemodialysis patients

References

• Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2018–2208.
   Web of Science ®Google Scholar
• Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005;67(3):1179–1187.
   PubMed Web of Science ®Google Scholar
• Fukagawa M, Kido R, Komaba H, et al. Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding. Am J Kidney Dis. 2014;63(6):979–987.
   PubMed Web of Science ®Google Scholar
• Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) guideline update: what’s changed and why it matters. Kidney Int. 2017;92(1):26–36.
   PubMed Web of Science ®Google Scholar
• Floege J, Kim J, Ireland E, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant. 2011;26(6):1948–1955.
   PubMed Web of Science ®Google Scholar
• Natoli JL, Boer R, Nathanson BH, et al. Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysis. BMC Nephrol. 2013;14:88.
   PubMed Web of Science ®Google Scholar
• Kimata N, Albert JM, Akiba T, et al. Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: the Japan dialysis outcomes and practice patterns study. Hemodial Int. 2007;11(3):340–348.
   PubMedGoogle Scholar
• Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008;52(3):519–530.
   PubMed Web of Science ®Google Scholar
• Hong YA, Kim JH, Kim YK, et al. Low parathyroid hormone level predicts infection-related mortality in incident dialysis patients: a prospective cohort study. Korean J Intern Med. 2020;35(1):160–170.
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1–S201.
   PubMed Web of Science ®Google Scholar
• Janjua TK, Mukhtar KN, Naveed AK, et al. Frequency of maintenance hemodialysis patients meeting K/DOQI criteria for serum calcium, phosphorus, calcium phosphorus product and PTH levels; a single institutional experience from Pakistan: a cross sectional study. Pan Afr Med J. 2019;33:183.
   PubMed Web of Science ®Google Scholar
• Wei M, Taskapan H, Esbaei K, et al. K/DOQI guideline requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: can we achieve them? Int Urol Nephrol. 2007;38(3–4):739–743.
   Web of Science ®Google Scholar
• Toussaint ND, Pedagogos E, Beavis J, et al. Improving CKD-MBD management in haemodialysis patients: barrier analysis for implementing better practice. Nephrol Dial Transplant. 2011;26(4):1319–1326.
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;76(113):S1–S130.
   Google Scholar
• Cozzolino M. CKD-MBD KDIGO guidelines: how difficult is reaching the ‘target’? Clin Kidney J. 2018;11(1):70–72.
   PubMed Web of Science ®Google Scholar
• Fouque D, Roth H, Darné B, et al. Achievement of Kidney Disease: Improving Global Outcomes mineral and bone targets between 2010 and 2014 in incident dialysis patients in France: the Photo-Graphe3 study. Clin Kidney J. 2018;11(1):73–79.
   PubMed Web of Science ®Google Scholar
• Teo BW, Xu H, Wang D, et al. GFR estimating equations in a multiethnic Asian population. Am J Kidney Dis. 2011;58(1):56–63.
   PubMed Web of Science ®Google Scholar
• Cozzolino M, Messa P, Brancaccio D, et al. Achievement of NKF/K-DOQI recommended target values for bone and mineral metabolism in incident hemodialysis patients: results of the FARO-2 cohort. Blood Purif. 2014;38(1):37–45.
   PubMed Web of Science ®Google Scholar
• Villa-Bellosta R, Rodriguez-Osorio L, Mas S, et al. A decrease in intact parathyroid hormone (iPTH) levels is associated with higher mortality in prevalent hemodialysis patients. PLoS One. 2017;12(3):e0173831.
   PubMed Web of Science ®Google Scholar
• Soohoo M, Feng M, Obi Y, et al. Changes in markers of mineral and bone disorders and mortality in incident hemodialysis patients. Am J Nephrol. 2016;43(2):85–96.
   PubMed Web of Science ®Google Scholar
• Soleymanian T, Niyazi H, Noorbakhsh Jafari Dehkordi S, et al. Predictors of clinical outcomes in hemodialysis patients: a multicenter observational study. Iran J Kidney Dis. 2017;11(3):229–236.
   PubMed Web of Science ®Google Scholar
• Rivara MB, Ravel V, Kalantar-Zadeh K, et al. Uncorrected and albumin-corrected calcium, phosphorus, and mortality in patients undergoing maintenance dialysis. JASN. 2015;26(7):1671–1681.
   Web of Science ®Google Scholar
• Asada S, Yokoyama K, Miyakoshi C, et al. Relationship between serum calcium or phosphate levels and mortality stratified by parathyroid hormone level: an analysis from the MBD-5D study. Clin Exp Nephrol. 2020;24(7):630–637.
   PubMed Web of Science ®Google Scholar
• Avram MM, Mittman N, Myint MM, et al. Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis. 2001;38(6):1351–1357.
   PubMed Web of Science ®Google Scholar
• Merle E, Roth H, London GM, et al. Low parathyroid hormone status induced by high dialysate calcium is an independent risk factor for cardiovascular death in hemodialysis patients. Kidney Int. 2016;89(3):666–674.
   PubMed Web of Science ®Google Scholar
• Lee SA, Lee MJ, Ryu GW, et al. Low serum intact parathyroid hormone level is an independent risk factor for overall mortality and major adverse cardiac and cerebrovascular events in incident dialysis patients. Osteoporos Int. 2016;27(9):2717–2726.
   PubMed Web of Science ®Google Scholar
• Fukuma S, Fukuhara S, Shimizu S, et al. Population-level associations of achievement of targets for bone-mineral markers with survival in haemodialysis patients with mildly elevated intact-PTH levels: a case-cohort study. Sci Rep. 2019;9(1):11301.
   PubMedGoogle Scholar
• Waziri B, Musenge E, Duarte R, et al. Associations of plasma fibroblast growth factor 23 and other markers of chronic kidney disease-Mineral and bone disorder with all-cause mortality in South African patients on maintenance dialysis: a 3-year prospective cohort study. PLoS One. 2019;14(5):e0216656.
   PubMed Web of Science ®Google Scholar
• Covic A, Kothawala P, Bernal M, et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant. 2009;24(5):1506–1523.
   PubMed Web of Science ®Google Scholar
• Palmer SC, Hayen A, Macaskill P, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA. 2011;305(11):1119–1127.
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70(4):771–780.
   PubMed Web of Science ®Google Scholar